Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.
Coming December 2018
The treatment armamentarium of mCRPC has significantly evolved with the addition of hormonal agents such as Zytiga (Johnson & Johnson/Janssen) and Xtandi (Pfizer/Astellas). These targeted therapies have benefited efficacy outcomes and have favorable safety profiles. The management of mCRPC has been further transformed with the availability of therapeutic vaccine Provenge (Dendreon Pharmaceuticals) and radiopharmaceutical agent Xofigo (Bayer). Nevertheless, an enormous medical unmet need for better-tolerated novel therapies which could prolong overall survival and delay disease progression to a greater extent remains. Our unmet need module analyzes the key drivers of prescribing and identifies the most attractive commercial opportunities for drug developers.
Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.
Markets covered: United States, France, Germany, United Kingdom
Primary research: Survey of 60 U.S. and 30 European medical oncologists to be fielded in August 2018.
Key companies: Johnson & Johnson/Janssen, Pfizer/Astellas, Dendreon Pharmaceuticals, Bayer, and Sanofi.
Key drugs: Zytiga, Xtandi, Provenge, Xofigo, and Jevtana.